# A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci

> **NCT01519492** · PHASE2 · COMPLETED · sponsor: **Affinium Pharmaceuticals, Ltd** · enrollment: 103 (actual)

## Conditions studied

- Skin and Subcutaneous Tissue Bacterial Infections
- Wound Infection
- Cutaneous Abscess
- Burn Infection
- Cellulitis

## Interventions

- **DRUG:** AFN-12520000

## Key facts

- **NCT ID:** NCT01519492
- **Lead sponsor:** Affinium Pharmaceuticals, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2012-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01519492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01519492, "A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01519492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*